Insulin resistance and β-cell-dysfunction in insufficiently controlled type 2 diabetes: The SETT2D trial

Diabetes, Stoffwechsel und Herz

Volumn 16, Issue 2, 2007, Pages 91-97

  Pfützner, Andreas ^a,b,g   Pfutzner A H ^a   Stridde, E ^c   Huppertz, E ^d   Reimer, T ^a   Derwahl, M ^e   Forst, T ^a   Petrak, F ^f  

^a IKFE   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c PFIZER INC   (United States)

^d Sanofi Aventis Dt GmbH   (Germany)

^e IKFE   (Germany)

^f ST JOSEF HOSPITAL   (Germany)

^g Institute for Clinical Research and Development   (Germany)

Author keywords

cell dysfunction; Cardiovascular risk; Insulin resistance; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLITAZONE DERIVATIVE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIET THERAPY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KINESIOTHERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; TREATMENT OUTCOME;

EID: 34548436798     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444
2. Laakso M, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5: 294-315
3. Haffner SM, Lehto S, Rönnemaa T, Pyrörälä K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
4. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study 10 years later. Horm Metab Res 1985; 15 (Suppl): 41-46
5. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991; 11: 1068-1076
6. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G on behalf of the European Group for the Study of Insulin Resistance (EGIR): Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 100: 1166-1173
7. Bressler P, Bailey S, Matsuda M, DeFronzo RA: Insulin resistance and coronary artery disease. Diabetologia 1996; 39: 1345-1350
8. Buchanan T: Pancreatic Beta-Cell Loss and Preservation in Type 2 Diabetes. Clin Ther 2003; 23 (Suppl B): B32-B46
9. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975-980
10. Laakso M, Sarlund H, Mykkänen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Atherosclerosis 1990; 10: 223-232
11. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, Eriksson J: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 642-647
12. Hsue WA, Law R: Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105: 4S-14S
13. Haffner SM, D'Agostino R, Mykkänen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 1999; 22: 562-568
14. Bonora E: Relationship between regional fat distribution and insulin resistance. Int J Obes 2000; 24 (Suppl 2): S32-S35
15. D'Agostino RB, Ehrlich J, Stanford W, Schoenthagen S, Savage PJ, Rewers M: Insulin resistance predicts coronary artery calcification independent of CVD risk factors or diabetes status. Circulation 2000; 106: P68
16. Haffner SM, Williams K, Rozek MM, Stern MP: Homeostasis model assessment. Insulin resistance in relation to 8-years of incidence of cardiovascular diseases. Diabetologia 2000; 43 (Suppl 1): A295
17. Ruigomez A, Garcia Rodriguez LA: Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14: 439-445
18. Weerasuriya N, Siribaddana S, Wijeweera I, Dissanayeka A, Wijesekera J, Fernando DJ: The prevalence of peripheral neuropathy in newly diagnosed patients with non-insulin-dependent diabetes mellitus. Ceylon Med J 1998; 43: 19-21
19. Nordt TK, Bode C, Sobel BE: Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin. Diabetologia 2001; 44: 1121-1124
20. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG: Concentrations of proinsulin-like-molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly study. Diabetologia 2002; 45: 327-336
21. Haffner SM, D'Agostino R, Mykkänen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF: Proinsulin and insulin concentrations in relation to carotid wall thickness - Insulin resistance atherosclerosis study. Stroke 1998; 29: 1498-1503
22. Pfützner A, Standl E, Strotmann HJ, Schulze J, Hohberg C, Pahler S, Gottschall V, Lübben G: IRIS II Study: Type 2 Diabetics without Insulin Therapy in Germany: Epidemiological characteristics. Diabetes Stoffw Herz 2006; 15 (2): 9-16
23. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lübben G, Pahler S, Langenfeld M, Schulze J, Forst T: IRIS II Study: Intact Proinsulin is Confirmed as Highly Specific Marker for Insulin Resistance in a Cross-Sectional Study Design. Diab Technol Ther 2005; 7: 478-486
24. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Luebben G, Forst T: Fasting Intact Proinsulin is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes. Diabetes Care 2004; 27: 682-687
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
26. Hedblad B, Nilsson P, Janzon L, Berglund G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Med 2000; 17: 299-307
27. Pfützner A, Kunt T, Löbig M, Knesovic M, Forst T: Clinical and Laboratory Evaluation Characteristics of Two New Chemiluminescence Assays for Intact and Total Proinsulin. Clin Chem Lab Med 2003; 41: 1234-1238
28. Pfützner A, Pfützner AH, Kann P, Stute R, Löbig M, Yang JW, Mistry J, Forst T: Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Clin Lab 2005; 51: 734-738
29. Pfützner A, Forst T: Intaktes Proinsulin als kardiovaskulärer Risikomarker und prädiktiver diagnostischer Marker für die Insulinresistenz bei Patienten mit Typ 2 Diabetes. Diab Stoffw 2004; 14: 193-200
30. Forst T, Standl E, Hohberg C, Konrad T, Schulze J, Strotmann HJ, Lübben G, Pahler S, Bachinger A, Langenfeld M, Pfützner A: IRIS-II Study: The IRIS-II score - Assessment of a new clinical algorythm for the classification of insulin resistance in patients with type 2 diabetes. Diabet Med 2004; 21: 1149-1153
31. Schöndorf T, Maiworm A, Emission N, Forst T, Pfützner A: Biological Background and Role of Adiponectin as Marker for Insulin Resistance and Cardiovascular Risk. Clin Lab 2005; 51: 489-494
32. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH: Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992; 15: 666-692
33. Pfützner A, Kann P, Pfützner AH, Kunt T, Larbig M, Weber MM, Forst T: Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 Diabetes. Clin Lab 2004; 50: 567-573
34. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C: Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 2002; 7: 2153-2158
35. Pfützner A, Lorra B, Abdollhania M, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T: Preprandial Short-acting Insulin Analogue Substitution has an Immediate and Comprehensive β-Cell Protective Effect in Patients with Type 2 Diabetes Mellitus - Results from a Randomized Comparator Study vs. Glimepiride. Diab Technol Ther 2006; 8: 375-384
36. Petrak F, Stridde E, Crispin AA, Pfützner A: Development and Validation of a New Measure to Evaluate Psychological Resistance to Insulin Therapy. The Barriers to Insulin Therapy Questionnaire. Diabetes Care (accepted, in press)